TY - JOUR
T1 - Engaging and retaining abused women in perinatal home visitation programs
AU - Sharps, Phyllis
AU - Alhusen, Jeanne L.
AU - Bullock, Linda
AU - Bhandari, Shreya
AU - Ghazarian, Sharon
AU - Udo, Ifeyinwa E.
AU - Campbell, Jacquelyn
PY - 2013/11/1
Y1 - 2013/11/1
N2 - OBJECTIVES: Intimate partner violence (IPV) during pregnancy affects 0.9% to 17% of women and affects maternal health significantly. The impact of IPV extends to the health of children, including an increased risk of complications during pregnancy and the neonatal period, mental health problems, and cognitive delays. Despite substantial sequelae, there is limited research substantiating best practices for engaging and retaining high-risk families in perinatal home visiting (HV) programs, which have been shown to improve infant development and reduce maltreatment. METHODS: The Domestic Violence Enhanced Home Visitation Program (DOVE) is a multistate longitudinal study testing the effectiveness of a structured IPV intervention integrated into health department perinatal HV programs. The DOVE intervention, based on an empowerment model, combined 2 evidence-based interventions: A 10-minute brochurebased IPV intervention and nurse home visitation. RESULTS: Across all sites, 689 referrals were received from participating health departments. A total of 339 abused pregnant women were eligible for randomization; 42 women refused, and 239 women were randomly assigned (124 DOVE; 115 usual care), resulting in a 71% recruitment rate. Retention rates from baseline included 93% at delivery, 80% at 3 months, 76% at 6 months, and 72% at 12 months. CONCLUSIONS: Challenges for HV programs include identifying and retaining abused pregnant women in their programs. DOVE strategies for engaging and retaining abused pregnant women should be integrated into HV programs' federal government mandates for the appropriate identification and intervention of women and children exposed to IPV. Pediatrics 2013;132:S134-S139.
AB - OBJECTIVES: Intimate partner violence (IPV) during pregnancy affects 0.9% to 17% of women and affects maternal health significantly. The impact of IPV extends to the health of children, including an increased risk of complications during pregnancy and the neonatal period, mental health problems, and cognitive delays. Despite substantial sequelae, there is limited research substantiating best practices for engaging and retaining high-risk families in perinatal home visiting (HV) programs, which have been shown to improve infant development and reduce maltreatment. METHODS: The Domestic Violence Enhanced Home Visitation Program (DOVE) is a multistate longitudinal study testing the effectiveness of a structured IPV intervention integrated into health department perinatal HV programs. The DOVE intervention, based on an empowerment model, combined 2 evidence-based interventions: A 10-minute brochurebased IPV intervention and nurse home visitation. RESULTS: Across all sites, 689 referrals were received from participating health departments. A total of 339 abused pregnant women were eligible for randomization; 42 women refused, and 239 women were randomly assigned (124 DOVE; 115 usual care), resulting in a 71% recruitment rate. Retention rates from baseline included 93% at delivery, 80% at 3 months, 76% at 6 months, and 72% at 12 months. CONCLUSIONS: Challenges for HV programs include identifying and retaining abused pregnant women in their programs. DOVE strategies for engaging and retaining abused pregnant women should be integrated into HV programs' federal government mandates for the appropriate identification and intervention of women and children exposed to IPV. Pediatrics 2013;132:S134-S139.
KW - Domestic violence enhanced home visitation program
KW - Home visitation
KW - Intimate partner violence
KW - Violence during pregnancy
UR - http://www.scopus.com/inward/record.url?scp=84887043180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887043180&partnerID=8YFLogxK
U2 - 10.1542/peds.2013-1021L
DO - 10.1542/peds.2013-1021L
M3 - Article
C2 - 24187115
AN - SCOPUS:84887043180
SN - 0031-4005
VL - 132
SP - S134-S139
JO - Pediatrics
JF - Pediatrics
IS - SUPPL.2
ER -